Keyword Search
 
2018 | 2017
DateTitle 
04/11/18Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia
Nonclinical data featured in Science Translational Medicine show dual inhibition of MDM2 and MDMX restored p53 function and demonstrated strong response rates in AML model CAMBRIDGE, Mass., April 11, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced the publication of nonclinical results in Science Translational Medicine demonstrating the anti-cancer potential of A... 
Printer Friendly Version
04/02/18Aileron Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Encouraging interim clinical results from studies of ALRN-6924 and progress against new programs support advancement and expansion of portfolio development plan CAMBRIDGE, Mass., April 02, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2017. “2017 was a pivotal ye... 
Printer Friendly Version
03/28/18Aileron Therapeutics Announces Expansion of Scientific Advisory Board
Drs. Druker, List and Prives join Aileron’s pioneering efforts to advance its stapled peptide approach to restoring p53’s cancer-fighting function   CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that three leading oncology experts have joined its Scientific Advisory Board (SAB).    “We are honored that world-class scientists and p... 
Printer Friendly Version
03/19/18Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors
CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptides developing therapeutics for cancers and other diseases, today announced the appointment of Jeffrey A. Bailey as Chairman of its Board of Directors. Mr. Bailey brings more than 30 years of leadership experience in the healthcare industry across multiple functional areas including R&D, business development, finance and commercial operations. He c... 
Printer Friendly Version